Kinarus Therapeutics and the Great Health Companion Group (GHCG) in China are exploring a partnership to fund further development of KIN001, Kinarus’ potential treatment for idiopathic pulmonary fibrosis (IPF). Switzerland-based Kinarus and GHCG, a subsidiary of global China conglomerate Hakim Unique Group, are also looking into ways to…
Being diagnosed with a chronic illness changes everything. In addition to the physical changes, patients endure emotional, mental, and social ones as well. This is especially true for those of us thrown into the chronic illness world as a young adult, when our brains have just finished developing but our…
The pulmonary fibrosis (PF) patient population would likely become unhinged without the oversight of our caregivers. They have one of the hardest roles in the PF community. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, my wife, Susan, was sitting by my side. For…
TXR-1002, Aria Pharmaceuticals’ investigational candidate for idiopathic pulmonary fibrosis (IPF), effectively prevented the buildup of scar tissue, or fibrosis, in the lungs of a rat model of the disease. Its effectiveness was comparable to that of the approved IPF therapy, Ofev (nintedanib) and was consistent with findings…
PLN-74809, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF), will now be called bexotegrast, its maker, Pliant Therapeutics, announced in a corporate update. The change came after the International Nonproprietary Names Expert Group selected bexotegrast as the unique generic, or nonproprietary, name for the experimental therapy. The company also announced…
Being short of breath is the worst feeling I’ve ever experienced. Sadly, it’s been getting progressively worse since I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016. Shortness of breath, or dyspnea, is one of the most common IPF symptoms. It took 13 months of seeing…
Rail travel has long been shrouded in both mystery and romance. English novelist Agatha Christie famously wrote “Murder on the Orient Express,” a tale of intrigue involving one of her most famous characters, Hercule Poirot. American singer-songwriter Steve Goodman originally wrote and recorded “City of New Orleans,” a song about…
Bridge Biotherapeutics has launched a Phase 2a clinical trial to assess the safety, tolerability, and effectiveness of BBT-877 in people with idiopathic pulmonary fibrosis (IPF). The trial (NCT05483907) is expected to enroll around 120 IPF patients, ages 40 and older, in 50 clinical sites in North America,…
For all the time I’ve spent in my 31 years “sitting in the U-bend, thinking about death,” as Moaning Myrtle from the “Harry Potter” series says, facing the loss of a loved one hasn’t gotten any easier. In spite of all my pondering, reading, and writing on the subject of…
The Pulmonary Fibrosis Foundation (PFF) is welcoming applications for its 2023 PFF Scholars program, which helps fund early-stage investigators developing research to improve the outcomes of people with pulmonary fibrosis (PF). Each investigator will receive a two-year research grant totaling $100,000, which is an increase of $25,000 a scholar…
Get regular updates to your inbox.
